Scientists react to final NICE Guidance on the Cystic Fibrosis drug Kaftrio.
David Ramsden, Chief Executive of Cystic Fibrosis Trust, said:
“We’re pleased that as part of the process, NICE’s independent committee used their updated method of appraising medicines, giving extra weight to more severe diseases like cystic fibrosis. It is one of the first times this has been used for non-cancer medicines and recognises the severity of the life long, life limiting, genetic condition.
“This is an important moment for the CF community and a tribute to all their campaigning over so many years, but these medicines are not a cure and don’t work for everyone so there is still lots more to do.
“We won’t stop until everyone with CF can live a life without limits.”
Declared interests:
None received